|
|
||||||||
1 Dr Senckenbergische Anatomie, Institut fuer Anatomie II, Fachbereich Medizin, Johann Wolfgang Goethe-Universitaet, D-60590 Frankfurt/Main
2 Max-Planck-Institut fuer Physiologische und Klinische Forschung, W. G. Kerckhoff-Institut, Arbeitsgruppe Energiebilanz und Adipositas, D-61231 Bad Nauheim, Germany
3 Division of Energy Balance and Obesity, Rowett Research Institute, Aberdeen Centre for Energy Balance and Obesity, Aberdeen, Scotland AB21 9SB, United Kingdom
| ABSTRACT |
|---|
|
|
|---|
orexigenic and anorexigenic neuropeptides; arcuate hypothalamic nuclei; ventromedial hypothalamic nuclei; dorsomedial hypothalamic nuclei; central leptin signaling; in situ hybridization
| INTRODUCTION |
|---|
|
|
|---|
-melanocyte-stimulating hormone (
-MSH) (35). The DMN, PVN, and the lateral hypothalamus (LH) contain high numbers of the melanocortin-4 receptor (MC4R). These are activated by the anorexigenic peptide
-MSH. AGRP is coexpressed with NPY in the same population of neurons in the ARC (14). It acts as the natural antagonist of
-MSH at MC4R via competitive displacement (31) and can be considered as a neuropeptide for precise adjustment of the
-MSH/MC4R system. CART is coexpressed with POMC in neurons of the ARC (6); other sources of CART are the LH, PVN, and DMN.
Induction of NPY expression in the DMN is reported for lactating rats (25), diet-induced obese mice (13), tubby mice (12), obese Agouti yellow mice and obese homozygous (-/-) MC4R-deficient mice (21), but obesity is not necessarily associated with detectable NPY expression in the DMN, because obese ob/ob mice did not display any expression (21). NPY expression in DMN neurons is under the control of the melanocortinergic system (21);
-MSH normally binds at MC4R in the DMN and inhibits the NPY expression in this nucleus. The lack of MC4R might induce NPY expression in the DMN (21). In previous studies in the melanocortin-4 receptor gene knockout (MC4r-KO) model, the induced NPY expression in the DMN was only found in obese homozygous (-/-) mice but not in heterozygous (+/-) and wild-type (+/+) mice of unspecified age (21).
Here we present results obtained by investigating the expressions of NPY, POMC, AGRP, and CART in the ARC and the adjacent hypothalamic tissue comprising the DMN and VMN of 9-mo-old mice of each genotype and, for reasons of comparison, corresponding expression data obtained for young (35- to 56-day-old) mice. The results extend and complement previous findings on NPY and POMC expression in the ARC of young mice, which showed significant common regressions with body fat content for animals, irrespective of genotype at MC4r (34). In addition, we report that induced expression of NPY occurs in the DMN and VMN at the age of 9 mo not only in -/- but also in +/- and +/+ mice and that its expression level is distinctly dependent on body fat content and genotype.
| METHODS |
|---|
|
|
|---|
Determination of body fat content.
Two hours before the end of their daily light phase, the mice were exposed to CO2 gas for about 30 s and then decapitated. Brains were quickly removed and frozen on dry ice. Blood was collected in heparinized tubes on ice and centrifuged. Brains and plasma aliquots were stored at -80°C. Carcass mass was determined after removing stomach and intestine and emptying the bladder. Body fat content (fat mass as percentage of carcass mass) was evaluated by drying the carcasses at 75°C to constant weight followed by total body chloroform extraction in a Soxhlet apparatus and drying again to constant weight (27).
Plasma measurements.
For leptin measurements we used a mouse RIA kit (Linco, St. Charles, MO). As previously described (8), measurements were independently duplicated, and variability was decreased by correcting the data for interassay variability and buffer dilution using internal correction factors.
In situ hybridization.
In situ hybridization was carried out on coronal hypothalamic slices. The animals investigated covered the entire range of body fat contents found in body composition analysis for each age group. Neuropeptide expression in the ARC was quantified by densitometry in three (AGRP, 79 animals; CART, 81 animals) or four (NPY, 96 animals; POMC, 96 animals) independent experimental sets. In addition, areas adjacent to the ARC comprising DMN and VMN were controlled for neuropeptide expression and, in the case of CART, quantified in a subset of 55 animals. Each set comprised animals of all genotypes. Additionally, nonradioactive in situ hybridization for NPY and POMC was carried out in one experimental set to count neuropeptide-positive cells in the DMN and VMN. Neuropeptide expression was determined in adjacent 20-µm-thick coronal sections, equivalent to bregma -0.34 mm to -2.54 mm in the mouse brain according to Franklin and Paxinos (9). The sections were mounted on poly-L-lysine-coated slides and stored at -80°C. Prior to hybridization, sections were fixed in 4% paraformaldehyde. For histological control of the locations of ARC, DMN, and VMN, parallel sections were stained with cresyl violet or neutral red.
Antisense and sense probes were prepared for each investigated mRNA. For prepro-NPY mRNA, the probes were generated from a 0.5-kb fragment of rat cDNA cloned into BlueScript M13(-) vector. AGRP and POMC cDNA fragments were cloned from Siberian hamster hypothalamic cDNA and ligated into pGEM-T Easy as described in detail elsewhere (28). CART cDNA was amplified from total RNA from GH3 (rat pituitary) cells by random-primed RT-PCR amplification using techniques described in detail elsewhere (1).
For radioactive in situ hybridization, antisense and sense NPY, POMC, AGRP, and CART probes were labeled with 35S-UTP, as described (27). The 35S-labeled riboprobes were used at a concentration of
2 x 107 cpm/ml. After hybridization, slides were treated with RNase A, desalted with a final high-stringency wash, dehydrated, and apposed to Hyperfilm ß-max (Amersham). Autoradiographic images of the ARC were quantified using the Image-Pro Plus system (Media Cybernetics, Silver Spring, MD). Data were standardized with 14C-autoradiographic scales (Amersham Biosciences, Little Chalfont, UK). Gene expression was measured as the integrated intensity of the autoradiographic signal, i.e., as the background-corrected optical density integrated over all pixels in the hybridization area. Normally three sections of each brain were analyzed and data were averaged.
For nonradioactive in situ hybridization, antisense and sense NPY and POMC probes were labeled with digoxigenin (DIG)-11-UTP, according to the manufacturers instructions (Boehringer, Mannheim, Germany). After hybridization, slides were desalted with a final high-stringency wash. Specific labeling was visualized by incubation with antidigoxigenin serum coupled to alkaline phosphatase followed by 5-bromo-4-chloro-3-indolylphosphate/nitroblue tetrazolium (BCIP/NBT). Slides were then air dried and embedded with Entellan (Merck). Cells expressing NPY were counted separately in the VMN and DMN of each brain in three sections passing through the maximal extension of the two nuclei by an investigator without knowledge of genotype and fat content. Counts were averaged for each nucleus and pooled for statistical analysis, since the labeling in the VMN and DMN showed no differential changes.
For both assays, specificity was confirmed by control experiments using the sense probes. No hybridization signals were observed under these conditions.
Statistical evaluation.
For a given neuropeptide, the densitometric data obtained in each in situ hybridization run were standardized by z-transformation, using the SigmaStat program (SPSS, Chicago, IL), to permit common evaluation of the different runs. Regression analysis was then applied to the relationship between the standardized data on NPY, POMC, AGRP and CART expression and body fat content. Because the preceding study (34) had shown that males and females might differ in the absolute levels of neuropeptide expression and body fat mass, but not in the correlation of the standardized expression data with body fat content, males and females were commonly evaluated in this study. In addition, the general relationship between neuropeptide expression and body fat content of the mice was analyzed for potential influences of MC4R deficiency and age. Analysis of covariance (ANCOVA) was used to disclose the influence of genotype as categorical variable independently from that of continuous covariates, such as fat content or plasma leptin concentration, thereby "partializing out" (2) the covariate influence. ANCOVA was carried out with the Statistica program (StatSoft, Tulsa, OK).
NPY-expressing neurons marked by nonradioactive in situ hybridization in the DMN and VMN were counted in specimens from six animals of each genotype. Correlations between fat content and the number of NPY-expressing neurons determined in individual animals were calculated for each genotype. Regressions were analyzed for differences in slope or y-intercept. For the entire sample, ANCOVA was applied with genotype as factor and fat content or plasma leptin concentration as covariate to partialize out its influence.
| RESULTS |
|---|
|
|
|---|
|
In contrast, in the 9-mo-old animals neither body fat content nor plasma leptin concentration was significantly correlated with the standardized expression data for any of the neuropeptides. Therefore, those data pairs are presented individually in Fig. 1, with different genotypes being indicated by different symbol fillings. Although there is a considerable overlap in the range of body fat contents of the middle-aged +/+ and +/- animals with that of the younger animals (535%), the body fat contents of a substantial number of the 9-mo-old MC4R-deficient mice are higher, ranging between 35 and 60%. For NPY, the expression data are distributed over the same range as in the younger animals, but, in relation to fat content, most of these data are higher than those represented by the regression for the younger animals (Fig. 1A). For POMC, the expression data of the 9-mo-old animals of all three genotypes tend to be lower than in the younger animals. Especially in relation to body fat content, these data are clearly lower than those represented by the regression for the younger mice (Fig. 1B). For AGRP (Fig. 1C), expression data and body fat content in the 9-mo-old mice are related to each other within the same range as in the younger animals only for body fat contents <35%. At higher fat contents, however, AGRP expression levels are distinctly higher in these middle-aged animals and thus reveal a tendency similar to that found for the coexpressed NPY. For CART, on the other hand, the expression data of the 9-mo-old +/+ animals tend to be lower than those of the younger animals, whereas those of -/- mice mostly correspond to the range of the younger animals (Fig. 1D).
For statistical evaluation of genotype influences, the expression data were analyzed separately for the samples of the young and of the middle-aged animals by ANCOVA with genotype as factor and percent body fat content as covariate to partialize out its influence. The overall genotype effects were significant in the younger animals for the expression of each neuropeptide (P < 0.05 for CART and P < 0.01 for the others). By contrast, the middle-aged animals showed a significant dependence on genotype at MC4r only for AGRP expression (P < 0.01). Corresponding statistical evaluation with plasma leptin as covariate also confirmed genotype effects for all analyzed neuropeptides in the younger animals but revealed no significant genotype effects on either of the neuropeptides in the middle-aged animals.
Figure 2 demonstrates the direction of the genotype-dependent changes of the expression data in the young and middle-aged mice for each of the investigated neuropeptides. After partializing out the effect of body fat content by ANCOVA, NPY expression is highest in the -/- mice of each age group. The middle-aged animals, moreover, display a distinctly higher level of expression (P < 0.01 for the overall effect of age), with the difference to the younger animals being significant in the post hoc test for the +/- and the -/- genotype. POMC expression increased with the number of the defective alleles in the younger animals. This increase contrasts with a marked decrease in expression in the middle-aged -/- mice (P < 0.05 for the post hoc test and P < 0.01 for interaction between age and genotype). The genotype effects on AGRP expression are also deviant for the two age groups (P < 0.01 for interaction between genotype and age). The tendency for a decrease in expression with increasing gene dose seen in the younger animals is completely reversed in the middle-aged animals for which post hoc testing confirms significantly higher expression levels in the older compared with the younger +/- and -/- mice (P < 0.05). Only the levels of CART expression and their genotype dependence are similar in the two age groups.
|
Nonradioactive in situ hybridization confirmed the absence of NPY-expressing cells in the DMN or VMN of 35- and 56-day-old mice (n = 19), irrespective of genotype at MC4r. At 9 mo of age, however, labeled cells were clearly present in both nuclei and in each genotype (n = 6 each). Figure 3 compares examples of sections hybridized with the DIG-labeled probe from 56-day-old +/+ mice (Fig. 3, AC) with corresponding sections from 9-mo-old animals (Fig. 3, DF). In 9-mo-old +/+ animals, NPY-labeled cells are not restricted to the ARC, but occur also in the VMN and DMN. The cells in the VMN and DMN are scattered and thus countable, unlike in the ARC, where the NPY-labeled cells are densely clustered at each age. At variance with the radioactive in situ hybridization, the borders between the ARC and the DMN and VMN could be easily determined by the nonradioactive method and are indicated in the sections. Figure 4 illustrates for the 9-mo-old mice the genotype-dependent increase of the number of NPY-labeled cells in both the DMN and VMN. The NPY-labeled cells in the VMN and DMN were counted separately in coronal sections from six specimens of each genotype, but there was no evidence for differential increases in NPY expression in the two nuclei. Therefore the cell counts in the VMN and DMN were pooled for the statistical analysis assessing the relationship between the number of NPY-expressing cells with genotype and fat content. At variance with NPY, an induced POMC expression also could not be detected by nonradioactive in situ hybridization in the VMN and DMN in any group of animals investigated here (data not shown).
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Age-dependent changes of neuropeptide expression in the ARC.
The present study has disclosed modulatory influences of body fat content and MC4R deficiency during the time span from shortly after weaning to the end of the fertile period. During this period body fat content increases with age preceding its decline toward senescence. This biphasic course of fat content has, so far, not been particularly considered in studies investigating animals from early adulthood to old age. This would explain why the reported age-dependent changes in hypothalamic neuropeptide expression are, in part, contradictory (11, 10, 20, 23, 26, 30). The interpretation of age-related changes of neuropeptide expression patterns is further complicated by the possibility of growing leptin resistance with age, especially as obesity develops (33, 26). Studies at an age when animals were certainly leptin responsive and thus capable of negative feedback control of body fat content have shown that hypothalamic NPY mRNA levels are lower in 9-wk-old, sexually mature mice than in 6-wk-old, sexually immature mice (4). This suggests a suppressive negative feedback effect of increasing fat content on the expression of the orexigenic NPY. Previous studies in genetically obese mice (32) and rats (17) at ages up to 40 wk have not distinguished between primary influences of genotype and secondary effects of changing fat content on changes of hypothalamic NPY expression with age. Moreover, analyzing neuropeptide expression patterns in total hypothalami and not in distinct nuclei, as in the present study, may have precluded the disclosure of evidence for cause-and-effect relationships underlying the complex age-dependent patterns of neuropeptide expression demonstrated in the present study on wild-type and MC4R-deficient animals.
How do age, fat content, and genotype at MC4r interact in changing ARC neuropeptide expression?
The present study was designed to cover the period from young adulthood to the end of the fertile period during which leptin or insulin resistance is known to develop, i.e., a period of life carrying an increasing adiposity risk for humans as well. Here we found that influences of both body fat content and MC4R deficiency on neuropeptide expression in the ARC are distinct in the young mice but have become obscured in the middle-aged animals (Fig. 1). Growing leptin resistance with advancing age and increasing fat deposition, which is particularly prominent in MC4R-deficient mice, would explain why NPY expression in the ARC progressively escapes the negative feedback control exerted by the lipostatic hormone. The influence of MC4R deficiency on neuropeptide expression (disclosed after adjusting for differences in fat content by ANCOVA) also differs distinctly between young and middle-aged animals. Young animals display enhancing effects of MC4R deficiency on the expression of both the anorexigenic POMC and the coexpressed neuropeptide CART but divergent effects on the orexigenic NPY and the coexpressed AGRP, with the former being highest and the latter lowest in -/- mice of this age. In the middle-aged animals only the relation between CART expression levels and genotype remains similar to that found in the young animals. NPY expression is significantly stronger than in the younger +/- and -/- mice, and the same tendency is found for the +/+ mice. POMC expression is massively decreased in the middle-aged -/- mice, in contrast to the enhancing effect of the MC4R deficiency in the younger animals. The genotype effect on AGRP expression is opposite to the suppressive genotype influence in the younger animals, with the levels for the middle-aged +/- and -/- animals being equally enhanced relative to the +/+ mice of the same age. Taken together, the changing neuropeptide expression patterns with increasing age suggest that MC4R deficiency progressively alters the relationships between the central peptidergic pathways originating in the ARC which normally act as mutually inhibitory controllers of energy balance. This even includes altered relationships between peptides that are coexpressed. The resulting regulatory disturbance is characterized by the progressive impairment of body fat content-related feedback control.
Changing relationships among coexpressed neuropeptides in other animal models.
Changes in the levels of coexpressed neuropeptides in connection with disturbances of energy balance are described in various animal models. In Sprague-Dawley and lean heterozygous (+/fa) and obese homozygous (fa/fa) Zucker rats, the relationship between expression of NPY and AGRP was found to be differentially dependent on starvation and genotype, presumably due to differential sensitivities to leptin and other controlling factors, including insulin (22). Coexpression of POMC and CART in a distinct set of ARC neurons is probably less stringent, and quantitative differences in their expression have been reported in response to leptin administration to ob/ob mice (7). Altered relationships between coexpressed neuropeptides are thus not uncommon, although the factors controlling such changes are still obscure. The highly complex interactions between the peptidergic neurons under consideration (3, 5, 15), even to the extent of positive feedback influences (6), may be influential. Differential susceptibilities to MC4R deficiency, age, and other specific physiological parameters, e.g., feeding conditions (22, 29), may underlie the altered relationships between coexpressed neuropeptides seen in the present study.
Induced NPY expression in DMN and VMN reflects age, body fat content, and genotype at MC4r.
The results of radioactive in situ hybridization analysis have identified NPY as the only neuropeptide changing its expression in the DMN and VMN during the investigated age period, whereas POMC and AGRP signals were absent at each age and CART was expressed independent of age in the DMN in line with previous observations (18). Quantitative evaluation of induced NPY expression by nonradioactive in situ hybridization confirmed the absence of the NPY signal in the younger animals but its presence in the middle-aged animals. The tight positive correlation between the number of NPY-labeled cells in the DMN and VMN and body fat content (or plasma leptin concentration) is opposite to what would be expected if induced NPY expression in these nuclei would be subject to negative feedback control by body fat content. Rather, the observed genotype-dependently enhanced NPY expression in the DMN and VMN would suggest that its central hyperphagic action caused enhanced fat deposition and the consecutive rise of plasma leptin concentration. It is important to note that the tight positive correlation between NPY expression in the DMN and VMN and body fat content is established at an age at which NPY expression in the ARC still tends to decrease with increasing body fat content, albeit no longer significantly, suggesting remnants of its counter-regulatory control, probably by leptin as a fat content-dependent lipostatic signal.
Induced expression of NPY in the DMN and VMN has been previously described for several genetic models of obesity, including Agouti yellow mice (21), tubby mice (12), and -/- MC4r-KO mice (21). Although the age of the MC4r-KO mice was not specified in this study, their body weight suggests that they were 56 mo old (21, 16). At this age induced NPY expression was present in -/- but not yet in +/- and +/+ animals (21). All three models of obesity have in common a reduced functionality of the melanocortinergic system. Moreover, induced NPY expression has been observed in the DMN and VMN of rats in states of increased energy demand, i.e., during lactation (25), intense exercise, and food restriction (24). Induced NPY expression in the DMN is also found in diet-induced obese mice (13). Apart from confirming the age dependence of induced NPY expression, the present study demonstrates for the first time its tight positive relation to body fat content and plasma leptin concentration in wild-type as well as MC4R-deficient mice. The absence of the NPY signal in the 2-mo-old mice of all genotypes, its earlier occurrence in -/- mice (21), and its upward shift in the 9-mo-old -/- relative to the +/- and +/+ mice, indicate that the age-dependent onset of induced NPY expression in the DMN and VMN is enhanced by the complete lack of MC4R. The demonstration of NPY-expressing cells in the DMN and VMN appearing well after adulthood, although at an age usually exceeded by the life span of laboratory mice, does not exclude the possibility that in later stages NPY expression in +/- mice may also deviate from that in +/+ mice. The absence of POMC and AGRP expression and the stable constitutive expression of CART in the middle-aged animals also does not exclude further changes of the neuropeptide expression pattern in the DMN and VMN with advancing age.
| Perspectives |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
This work was supported by a doctoral stipend to J. Arens (Graduiertenkolleg 361: "Neuronale Plastizität: Moleküle, Strukturen, Funktionen," University Frankfurt/Main) and by the Federal Ministry of Education and Research in the framework of the National Genome Research Network Neuronetz Marburg (01GS0118), the German Science Foundation (Schm 680/4), and the Scottish Executive Environment and Rural Affairs Department (to K. M. Moar and J. G. Mercer).
| FOOTNOTES |
|---|
Address for reprint requests and other correspondence: I. Schmidt, Max-Planck-Institut, W.G. Kerckhoff-Institut, Parkstrasse 1, D-61231 Bad Nauheim, Germany (E-mail: ingrid.schmidt{at}kerckhoff.mpg.de).
10.1152/physiolgenomics.00123.2003.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
L. S. Tallam, A. A. da Silva, and J. E. Hall Melanocortin-4 Receptor Mediates Chronic Cardiovascular and Metabolic Actions of Leptin Hypertension, July 1, 2006; 48(1): 58 - 64. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kuramochi, T. Onaka, D. Kohno, S. Kato, and T. Yada Galanin-Like Peptide Stimulates Food Intake via Activation of Neuropeptide Y Neurons in the Hypothalamic Dorsomedial Nucleus of the Rat Endocrinology, April 1, 2006; 147(4): 1744 - 1752. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Liang and B. Ventura Physiological genomics in PG and beyond: July to September 2005 Physiol Genomics, October 17, 2005; 23(2): 119 - 124. [Full Text] [PDF] |
||||
![]() |
C. Fekete, D. L. Marks, S. Sarkar, C. H. Emerson, W. M. Rand, R. D. Cone, and R. M. Lechan Effect of Agouti-Related Protein in Regulation of the Hypothalamic-Pituitary-Thyroid Axis in the Melanocortin 4 Receptor Knockout Mouse Endocrinology, November 1, 2004; 145(11): 4816 - 4821. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |